Japan CRISPR-Cas9 Gene Editing Market (2033): CRISPR Reagents, Gene & Cell Therapy and Biotechnology R&D Growth in Japan Expansion

DataM Intelligence has released a new research report titled "Japan CRISPR-Cas9 Gene Editing Market Size 2026". The report delivers in-depth insights into key market dynamics, including market segmentation, CAGR projections, end-user trends, technology adoption, and the competitive landscape. It also highlights major growth drivers shaping Japan's gene-editing ecosystem. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of value and volume, along with emerging opportunities and the overall development outlook of the Japan CRISPR-Cas9 Gene Editing market.

Download Sample Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/japan-crispr-cas9-gene-editing-market?sindhuri

Recent Key Developments - Japan & Regulatory Landscape
✅ July 2026: Japan moved human germline genome editing from guidance toward binding regulation. On July 17, Japan enacted the Act on Regulation of Handling of Human Genome-Edited Embryos, etc., introducing legally enforceable controls around the handling of human genome-edited embryos. The legislation addresses areas including in-utero implantation, handling procedures, reporting requirements, record keeping, and restrictions on the creation and transfer of genome-edited embryos.

✅ August-September 2026: Government committees continued defining how the new genome-editing framework will operate in practice. Japan's Ministry of Health, Labour and Welfare held meetings in July, August and September to examine the scope of genome-editing technologies covered by the rules and the treatment of human genome-edited embryos, including proposed ministerial regulations and guidelines.

✅ July 2026: Japan also strengthened the infrastructure around gene-therapy commercialization. The Ministry of Health, Labour and Welfare launched the portal for the FY2026 Gene Therapy Commercialization Support Consortium, creating a dedicated platform to support companies and research organizations working toward practical implementation of gene therapies.

Recent Key Developments - CRISPR Delivery & Safety Innovation
✅ June 2026: Kyoto University and Takeda demonstrated a safety advantage for LNP-based CRISPR delivery. A joint CiRA-Takeda research team found that lipid nanoparticles (LNPs) produced almost no detectable foreign-DNA integration at CRISPR editing sites in mice, while AAV delivery showed vector-fragment insertion. LNP editing efficiency also remained broadly stable after repeat dosing, unlike the substantial reduction observed with AAV.

✅ June 2026: Japan researchers introduced a multi-layer method for detecting CRISPR off-target changes. The Kyoto University team combined computational prediction, CIRCLE-seq laboratory testing and whole-genome sequencing of human iPS cells. The integrated approach narrowed the genome-wide search to 11 high-confidence off-target candidate sites, providing a more stringent framework for safety assessment of therapeutic genome editing.

Recent Key Developments - Genome-Editing Technology & Commercial Applications
✅ September 2026: AIST and Japanese partners developed a smaller domestically developed genome-editing tool. AIST, TOPPAN Holdings and Implanta Innovation reported the development of AsaTnpB-L, a compact DNA-cutting system derived from a bacterial protein. Its smaller size is intended to address a key delivery challenge associated with larger genome-editing systems, and the technology has received a Japanese patent.

✅ August 2026: Sanatech Life Science completed Japan's regulatory notification for a multi-trait CRISPR tomato. The University of Tsukuba-originated company completed notification procedures with Japan's Consumer Affairs Agency and Ministry of Agriculture, Forestry and Fisheries for tomato lines engineered to combine high GABA and high cis-lycopene. The development used simultaneous editing of two genes, demonstrating the move toward stacking multiple commercially useful traits in a single genome-edited crop.

List of Key Players 2026:
Takeda Pharmaceutical, Daiichi Sankyo, Astellas Pharma, Takara Bio, Sumitomo Chemical, Thermo Fisher Scientific, Merck KGaA, GenScript, DH Life Sciences and Illumina.

Company Evaluation
Leading pharmaceutical companies such as Takeda, Daiichi Sankyo and Astellas Pharma are advancing CRISPR-based gene-editing research across oncology, rare diseases and precision medicine.

Companies including Takara Bio, Thermo Fisher Scientific, Merck KGaA and GenScript support market growth through CRISPR reagents, gene-editing kits, sequencing and research solutions.

Growth Forecast Projected 2026:
The Japan CRISPR-Cas9 Gene Editing Market is projected to grow from USD 268.5 million in 2025 to USD 856.4 million by 2033, registering a 15.6% CAGR during 2026-2033. Growth is driven by precision medicine, genomic research, biotechnology R&D and CRISPR-based therapeutic development.

Get 20% Complimentary Customization Within the Report:
https://www.datamintelligence.com/customize/japan-crispr-cas9-gene-editing-market?sindhuri

M&A / Strategic Activity
Recent strategic partnerships, licensing agreements, and ecosystem developments shaping the Japan CRISPR-Cas9 Gene Editing Market:

C4U Corporation - Expansion of Japan's domestically developed genome-editing ecosystem
C4U has been building a commercial ecosystem around its Japan-developed CRISPR-Cas3 platform, including licensing and collaborative research with pharmaceutical, biotechnology, and research organizations. In 2026, the company expanded this model through agreements with Euglena, FRONTEO, and Cellafa Bioscience, alongside its existing collaborations with RACTHERA, Kyoto University's CiRA, and other partners.

C4U and Euglena - From genome editing research to test production
In January 2026, C4U granted Euglena a non-exclusive license covering CRISPR-Cas3 patents for test production. The agreement followed collaborative work that successfully produced genome-edited Euglena strains with potential industrial applications, moving the relationship beyond laboratory research toward production testing for food and other products.

C4U and RACTHERA - Second CRISPR-Cas3 licensing agreement
C4U signed a second licensing agreement with RACTHERA in December 2025 after joint research into cells and genes for regenerative-medicine products. The collaboration originated with Sumitomo Pharma in 2021 and continued under RACTHERA after it succeeded Sumitomo Pharma's regenerative and cellular medicine business in February 2025.

C4U and Kyoto University CiRA - Disease-focused genome-editing development
C4U and the Hotta Laboratory at Kyoto University's Center for iPS Cell Research and Application entered a new collaboration in December 2025 to develop therapeutic approaches for Duchenne muscular dystrophy using CRISPR-Cas3. The program combines patient-derived iPSC evaluation systems and skeletal-muscle delivery research with C4U's genome-editing technology.

C4U and iXgene - CRISPR editing combined with iPSC technology
In September 2026, C4U and iXgene entered a collaborative research agreement covering a novel cell-therapy approach that combines iXgene's iPSC platform with C4U's CRISPR-Cas3 technology. The parties are conducting non-clinical studies, with iXgene receiving an option to negotiate an exclusive patent license for products arising from the collaboration.

New Product/Technology Launches & Deployments
Recent technology developments are broadening Japan's genome-editing landscape beyond conventional Cas9 applications:

C4U - CRISPR-Cas3 moves toward therapeutic T-cell applications
In April 2026, C4U, Noile-Immune Biotech, and a University of Tokyo research team reported successful application of CRISPR-Cas3 to human T cells. The work demonstrated clinically relevant genetic modifications and was positioned as a step toward allogeneic CAR-T applications, particularly where researchers are seeking alternatives to Cas9-associated off-target and chromosomal-abnormality concerns.

C4U - In-vivo genome editing platform advances
Research led by University of Tokyo Professor Tomoji Mashimo and associated with C4U has advanced an in-vivo CRISPR-Cas3 approach using mRNA-LNP delivery. The program is being developed toward therapeutic genome editing, including work targeting inherited and cardiovascular-related diseases. AMED has also selected the CRISPR-Cas3 mRNA-LNP program for continued development.

AIST, TOPPAN and Inplanta Innovations - Small Japanese genome-editing tool
In September 2026, AIST, TOPPAN Holdings, and Inplanta Innovations reported a new compact genome-editing tool called AsaTnpB-L. The engineered nuclease is approximately 600 amino acids, compared with 1,368 amino acids for SpCas9, and achieved around 60% editing efficiency in human cultured cells. The team also demonstrated genome-editing capability in plants and obtained Japanese patent protection.

Sumitomo Chemical - Domestic GMP manufacturing of long guide RNAs
Sumitomo Chemical has established an oligonucleotide manufacturing facility in Oita specifically supporting high-purity guide RNA production for genome-editing applications. The facility began operating in 2023, with the company subsequently demonstrating GMP production of 130-mer gRNA and offering manufacturing support from development through potential commercial production.

C4U - CRISPR-Cas3 industrial deployment through Euglena
The successful editing of microalgae and subsequent licensing arrangement with Euglena demonstrates an unusual Japanese commercialization pathway: genome editing is being extended from therapeutic research into food, biomaterials, and other industrial applications. Euglena has specifically identified potential future applications involving higher production of useful ingredients and fine chemicals.

R&D & Technological Advancements
Shift toward smaller genome-editing systems
Japanese research is increasingly addressing one of the practical limitations of conventional Cas9 systems: delivery. AIST's AsaTnpB-L work illustrates this direction, using a substantially smaller nuclease while retaining guide-RNA-directed DNA cutting. The research team used predicted protein structures to identify candidates and optimize the editing system, rather than relying solely on conventional sequence-based screening.

CRISPR-Cas3 as a Japanese alternative platform
C4U is developing Cas3 as a separate genome-editing platform with a longer guide-recognition sequence and the ability to create larger DNA deletions. Its commercial strategy also benefits from an independent patent portfolio, providing an alternative licensing route to the more complex Cas9 intellectual-property landscape.

In-vivo editing using mRNA-LNP delivery
Japan's research pipeline is moving toward direct delivery of genome-editing machinery inside the body rather than relying exclusively on ex-vivo cell manipulation. AMED's supported CRISPR-Cas3 mRNA-LNP program at the University of Tokyo is specifically investigating an in-vivo therapeutic platform and has progressed into further development activities.

Genome editing combined with iPSC and cell therapy platforms
Collaborations involving C4U, Kyoto University's CiRA, iXgene, and RACTHERA show that genome editing is increasingly being integrated with iPSC and regenerative-medicine platforms. This creates development pathways in which edited cells become the therapeutic product rather than genome editing being used only as a laboratory research tool.

Patent positioning is becoming a commercial strategy
C4U received additional Japanese patent protection for its CRISPR-Cas3 platform in 2025 and 2026. A divisional patent issued in Japan in June 2026 expanded the company's protected technology base, while earlier Japanese patents were maintained following third-party oppositions.

Purchase This Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=japan-crispr-cas9-gene-editing-market?sindhuri

Segments Covered in the Japan CRISPR Cas9 Gene Editing Market:
By Product
The market is segmented into CRISPR Cas9 reagents, instruments and systems, and software and platforms. Reagents include Cas9 enzymes, guide RNAs, vectors, plasmids, buffers, and kits, while instruments and software support gene-editing workflows, design, and data analysis.

By Technology
The market is divided into CRISPR Cas9 nuclease editing, CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), base editing, and others. Nuclease editing holds a key position, while CRISPRi, CRISPRa, and base editing are gaining adoption for gene regulation and precise genetic modifications.

By End-User
The market is categorized into pharmaceutical and biotechnology companies, academic and government research institutes, clinical research organizations, CROs, hospitals and diagnostic centers, and agricultural and food biotechnology firms. Pharmaceutical and biotechnology companies represent a significant share, supported by investment in gene-editing research, drug discovery, and therapeutic development.

By Application
The market is segmented into gene and cell therapy, drug discovery and development, functional genomics, disease modeling, diagnostics, agricultural biotechnology, and others. Gene and cell therapy is a major application area, while drug discovery, functional genomics, and disease modeling continue to expand.

By Delivery Method
The market is categorized into viral, non-viral, and physical delivery methods. Viral delivery is widely used for efficient gene-editing component delivery, while lipid-based, nanoparticle-based, electroporation, and microinjection methods support emerging and specialized applications.

By Disease Area
The market is segmented into oncology, genetic disorders, infectious diseases, cardiovascular diseases, neurological disorders, and others. Oncology represents a significant area due to research into gene-editing-based cancer therapies, while genetic disorders remain a major focus for targeted gene modification.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.